Cigna Group’s patent outlines methods for modifying medication regimens to reduce drug waste. It involves analyzing prescription data, comparing waste levels to a threshold, and identifying alternative regimens with lower waste while maintaining efficacy. The system also includes a user interface for selecting and updating medication options. GlobalData’s report on Cigna Group gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Cigna Group, Social media analytics was a key innovation area identified from patents. Cigna Group's grant share as of July 2024 was 63%. Grant share is based on the ratio of number of grants to total number of patents.
Dose regimen modification to reduce drug waste
The patent US12073931B2 outlines a method and system for optimizing medication regimens to minimize drug waste while maintaining expected treatment efficacy. The process begins with the receipt of prescription-related data, which includes medication regimen details such as dosage and administration intervals. A model is employed to calculate the initial amount of drug waste associated with the prescribed regimen. If this waste exceeds a predetermined threshold, the system identifies alternative medication regimens that achieve the same efficacy but with reduced waste. A graphical user interface (GUI) is then generated, allowing healthcare providers to interactively explore various medication options, select alternatives, and update the prescription details accordingly.
The method further incorporates machine learning techniques to refine the model based on training data, which includes features from previously selected regimens. The system can evaluate multiple alternative regimens, considering factors such as waste levels, adherence rates, and side effects. Specific criteria, such as a waste value below the threshold or a zero waste value, guide the selection of the most appropriate alternative. The patent also specifies that the threshold for drug waste can be set at 14 milligrams per dose or more, and it highlights the potential application of this method to drugs like monoclonal antibodies with linear pharmacokinetics. Overall, this innovation aims to enhance medication management by reducing waste and improving treatment outcomes through data-driven decision-making.
To know more about GlobalData’s detailed insights on Cigna Group, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies across the world’s largest industries.
